Primary |
Pulmonary Arterial Hypertension |
23.1% |
Prophylaxis |
19.2% |
Hypertension |
15.4% |
Atrial Fibrillation |
7.7% |
Atrial Flutter |
7.7% |
Metastatic Renal Cell Carcinoma |
7.7% |
Arteriosclerosis Coronary Artery |
3.8% |
Bladder Disorder |
3.8% |
Deep Vein Thrombosis |
3.8% |
Depression |
3.8% |
Pollakiuria |
3.8% |
|
Dizziness |
11.1% |
Gastroenteritis Viral |
11.1% |
Gastrointestinal Haemorrhage |
11.1% |
Haematemesis |
11.1% |
Hepatic Fibrosis |
11.1% |
Hypocalcaemia |
11.1% |
Liver Injury |
11.1% |
Melaena |
11.1% |
Skin Disorder |
11.1% |
|
Secondary |
Drug Use For Unknown Indication |
17.7% |
Product Used For Unknown Indication |
15.0% |
Atrial Fibrillation |
9.2% |
Chronic Obstructive Pulmonary Disease |
7.8% |
Hypertension |
7.5% |
Suicide Attempt |
5.2% |
Thrombosis Prophylaxis |
4.6% |
Cardiac Failure |
3.6% |
Atrial Flutter |
3.1% |
Hypokalaemia |
3.0% |
Anticoagulant Therapy |
2.9% |
Coronary Artery Disease |
2.6% |
Prophylaxis |
2.6% |
Accidental Exposure |
2.6% |
Supraventricular Tachycardia |
2.5% |
Epilepsy |
2.3% |
Pulmonary Arterial Hypertension |
2.3% |
Major Depression |
2.1% |
Sedation |
1.7% |
Dermatitis |
1.6% |
|
Toxic Epidermal Necrolysis |
17.2% |
International Normalised Ratio Increased |
16.0% |
Prothrombin Time Prolonged |
11.0% |
Suicide Attempt |
6.1% |
Transaminases Increased |
6.1% |
White Blood Cell Count Increased |
4.3% |
Gastrointestinal Haemorrhage |
3.7% |
Thrombocytopenia |
3.7% |
Bradycardia |
3.1% |
Leukocytoclastic Vasculitis |
3.1% |
Prothrombin Time Shortened |
3.1% |
Stevens-johnson Syndrome |
3.1% |
Anaemia |
2.5% |
Coagulation Time Abnormal |
2.5% |
Drug Interaction |
2.5% |
Hypoaesthesia |
2.5% |
Nausea |
2.5% |
Premature Baby |
2.5% |
Renal Failure |
2.5% |
Renal Failure Acute |
2.5% |
|
Concomitant |
Product Used For Unknown Indication |
25.3% |
Drug Use For Unknown Indication |
15.9% |
Hypertension |
12.1% |
Atrial Fibrillation |
10.9% |
Rheumatoid Arthritis |
6.1% |
Cardiac Failure |
3.4% |
Pulmonary Arterial Hypertension |
3.2% |
Osteoporosis |
2.7% |
Diabetes Mellitus |
2.4% |
Prophylaxis |
2.2% |
Thrombosis Prophylaxis |
2.1% |
Pain |
1.8% |
Multiple Myeloma |
1.8% |
Depression |
1.8% |
Pulmonary Hypertension |
1.7% |
Coronary Artery Disease |
1.6% |
Anticoagulant Therapy |
1.3% |
Arrhythmia |
1.3% |
Breast Cancer |
1.3% |
Type 2 Diabetes Mellitus |
1.2% |
|
Vomiting |
8.1% |
Thrombocytopenia |
7.2% |
Pulmonary Embolism |
6.5% |
Renal Failure |
6.5% |
Pyrexia |
5.8% |
Prothrombin Time Prolonged |
5.6% |
Death |
5.4% |
Renal Failure Acute |
5.4% |
Syncope |
5.4% |
Weight Decreased |
5.1% |
Pneumonia |
4.9% |
Tachycardia |
4.9% |
Weight Increased |
4.2% |
Transaminases Increased |
4.0% |
Atrial Fibrillation |
3.8% |
Dyspnoea |
3.6% |
Rhabdomyolysis |
3.6% |
Nausea |
3.4% |
Ventricular Fibrillation |
3.4% |
Cardiac Failure |
3.2% |
|
Interacting |
Drug Use For Unknown Indication |
22.9% |
Hypertension |
13.6% |
Product Used For Unknown Indication |
12.5% |
Atrial Fibrillation |
12.2% |
Type 2 Diabetes Mellitus |
5.0% |
Helicobacter Gastritis |
4.3% |
Pain |
3.9% |
Insomnia |
3.6% |
Atrial Flutter |
3.2% |
Hairy Cell Leukaemia |
2.2% |
Cardiac Disorder |
1.8% |
Goitre |
1.8% |
Mitral Valve Stenosis |
1.8% |
Oedema Peripheral |
1.8% |
Pulmonary Embolism |
1.8% |
Syncope |
1.8% |
Deep Vein Thrombosis |
1.4% |
Diabetes Mellitus |
1.4% |
Mitral Valve Replacement |
1.4% |
Myocardial Ischaemia |
1.4% |
|
International Normalised Ratio Increased |
18.5% |
Drug Interaction |
17.4% |
Prothrombin Time Prolonged |
13.0% |
Prothrombin Time Shortened |
6.5% |
Melaena |
5.4% |
Prothrombin Time Abnormal |
5.4% |
Drug Effect Increased |
3.3% |
Hemiparesis |
3.3% |
International Normalised Ratio Decreased |
3.3% |
Renal Failure Acute |
3.3% |
International Normalised Ratio |
2.2% |
Muscle Haemorrhage |
2.2% |
Prothrombin Level Decreased |
2.2% |
Shock Haemorrhagic |
2.2% |
Somnolence |
2.2% |
Subarachnoid Haemorrhage |
2.2% |
Thrombin Time Abnormal |
2.2% |
Transaminases Increased |
2.2% |
Weight Decreased |
2.2% |
Blood Glucose Increased |
1.1% |
|